Running a clinical trial in 2026 involves managing more operational complexity than at any previous point in the history of drug development. Multi-site, multi-country studies with hundreds of participating investigators, thousands of patients, and real-time data obligations to regulators have made the spreadsheet-and-email approach to trial management not just inefficient but genuinely risky. For pharmaceutical companies, contract research organisations, and biotech firms, c

Regulatory affairs teams in pharmaceutical and life sciences companies are managing more complexity than at any previous point in the industry's history. The volume of global submissions is growing, health authorities are raising the bar on data standards - IDMP compliance deadlines are approaching across the EU and beyond - and the shift to eCTD 4.0 is creating real transition demands for organisations that have spent years building workflows around earlier standards. At the

Pharmaceutical manufacturing sits at one of the most demanding intersections of operational complexity and regulatory obligation in any industry. Getting a batch to market requires not just efficient production, but an unbroken chain of documentation, quality control, and audit-ready records that stand up to scrutiny from the FDA, EMA, MHRA, or any combination of global regulators. ERP systems are the foundation beneath all of that - and choosing the wrong one carries consequ

Pharmaceutical organisations run some of the most complex and compliance-intensive technology environments in any industry. From clinical trial management and regulatory submissions through to GMP manufacturing execution, quality management, and serialised supply chain, the software stack that keeps a pharma business operating and compliant spans a wide range of specialist platforms - each with its own regulatory expectations, validation requirements, and integration dependen